Amyris, Inc. today announced that it has closed the acquisition of the assets of MenoLabs, LLC.
EMERYVILLE, Calif., March 11, 2022 /PRNewswire/ -- Amyris, Inc., (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform today announced that it has closed the acquisition of the assets of MenoLabs, LLC, a company founded by women to treat menopause symptoms, drive research for women’s health and improve society’s understanding of menopause. MenoLabs, a growing women’s wellness brand, is focused on addressing perimenopause and menopause symptoms and offers research-backed, all-natural treatments for menopause symptoms. Over the past two years, MenoLabs has developed and launched eight products, including its lead product, MenoFit, an all-natural menopause relief supplement. MenoLabs generates a subscription-based, recurring revenue stream through its online sales, in addition to the Subscribe & Save option offered via the Amazon channel. The company is further expanding through retail channels in 2022. Additionally, MenoLabs offers MenoLife, a highly rated perimenopause and menopause health tracker app which helps users track and analyze more than 40 menopause-related symptoms. About Amyris Amyris, the Amyris logo and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries. About MenoLabs View original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-closes-acquisition-of-menolabs-301500717.html SOURCE Amyris, Inc. | ||
Company Codes: NASDAQ-NMS:AMRS |